bioAffinity Popped 44% on a Surveillance Story. The Cash Bridge Isn't Built Yet

In late July, Nasdaq told bioAffinity Technologies its listing was on the line because the shares kept closing below $1. On Tuesday the stock closed up 44% at $6.59, and traders exchanged roughly 46 million shares — about $330 million of turnover against a company worth on the order of $10 million.

The trigger was a press release, not a result. Management said it is advancing CyPath Lung, its marketed noninvasive test for lung cancer, into a new role: surveillance of patients who have completed curative-intent treatment. "Advancing" is doing careful work in that sentence. There was no new clinical data, no new reimbursement decision, and no revenue forecast in the announcement.

The market being pointed at is real and large. More than 680,000 Americans are living with a history of lung cancer, and recurrence after treatment for early-stage non-small cell lung cancer runs roughly 20% to 55% depending on stage and treatment. Today's standard follow-up is imaging every six months for two years after curative treatment, then annual CT scans. Imaging has a known blind spot: after surgery or radiation, scar tissue and inflammation can look like cancer, and a new nodule could be benign, a recurrence, or a separate new cancer. CyPath Lung reads a sputum sample by flow cytometry and artificial intelligence and returns a binary answer — "unlikely" or "likely" malignancy — positioned to sit alongside imaging and help decide who needs a closer look and who can keep scanning.

That is a coherent clinical wedge, but a thesis is not a financial fact. Nothing in Tuesday's release changed what the test sells for, whether insurers will pay in this new setting, or how many patients will receive it. The stock re-rated by roughly half anyway. That tells you what the day was: investors paying up for a story the company just told about itself.

Now the part worth taking seriously, because it is the raw material of a real expectations reset. CyPath Lung is not a concept. It has carried a CPT code (0406U) since October 2023, a finalized Medicare payment determination effective January 2024, and a $2,900 list price. And the operating numbers are inflecting. Test revenue rose 87% in 2025 while volumes rose 99%. In the first quarter of 2026, revenue rose 114% on 146% more units. In the second quarter, revenue reached about $835,000, up 159%, on 216% more tests, and the number of physician offices ordering the test rose 69% in the first quarter. That is the shape of a business improving underneath a stock the market had nearly given up on.

Because growth off a tiny base is not the same as growth that covers the bills, look closely at the composition. Volume keeps rising faster than revenue — 216% more tests against 159% more dollars in the second quarter. Units are outrunning dollars, which means the realized price per test is slipping as volume scales. That is the first thing I would check every quarter. And the whole company is still small: total second-quarter revenue was $1.51 million, and the flagship test booked roughly $1.2 million in the first half — an annual pace of a couple of million dollars.

That scale matters because the burn is not small. The company lost about $7 million in the first half of 2026, and cash went out at roughly $3 million to $4 million a quarter before any financings are counted; cash at June 30 was $2.4 million. There is no free cash flow here, so the preferred proof — the hard cash bridge — is absent. The honest alternative anchor is the unit economics themselves: whether volume can eventually outrun the cost base. The uncertainty attached to that anchor is high, and it should be labeled as such.

Which raises the unavoidable question: where does the difference come from? So far, from selling stock. The company took in about $16.9 million of gross proceeds from equity in 2025 alone, and its reported share count rose from about 519,000 at the end of 2024 to roughly 4.5 million a year later — nearly nine times, on the split-adjusted basis it reports. The pattern continued into 2026: a $3.2 million offering in the spring, then a $4 million private placement in August that issued 8.46 million shares plus warrants. In late July Nasdaq staff had issued a delisting determination for the sub-$1 trading, denied the standard 180-day cure because the company had already reverse-split within two years, and bioAffinity said it would appeal to a hearings panel — which stays any delisting while the case is pending. It then executed a 1-for-15 reverse split on August 24, its second in eleven months, after a 1-for-30 the prior September. Last week it registered up to 1.7 million shares for resale by the warrant holders who funded the recent rounds; exercising those for cash would add about $8 million and push outstanding shares toward 2.3 million.

So the tape is telling two stories at once. The headline is a huge survivor market — the company itself puts the U.S. addressable market for pulmonary nodule management and surveillance at $3.58 billion. The financial narrative underneath is a company running annual losses around $14 million while the flagship product books a fraction of that, with the gap filled by new shares rather than earnings. Two reverse splits in eleven months are not a detail; they are the visible cost of that funding model.

Here is the disciplined read. The operating story is real and improving, which is the necessary first half of an expectations reset. What is missing is the second half: the financial bridge. The proof that would convert this from a story into an investable idea is concrete and checkable in each quarterly report — growth that keeps outrunning the cash burn, a closing of the gap between unit growth and dollar growth, and contribution margin from test volume covering more of the fixed cost. On the clinical side, the longitudinal study partly funded by the Department of Defense, expected to run across up to 20 sites including VA and military hospitals, is the kind of data that would make payers comfortable in the surveillance setting; the company's earlier case study of a survivor whose second lung cancer was flagged by the test is an anecdote that precedes evidence, not the evidence itself.

What would break the case is equally specific: another large dilutive financing at a low price, a stall in unit growth, or a reimbursement or coverage stumble in the new indication. I can be wrong again — surveillance of lung cancer survivors is a genuinely large unmet need. But Tuesday priced the story, not the numbers. The numbers that would justify the move show up quarterly, in the same cash statement that keeps being rescued by new stock sales. Let the market chase the press release without you, and buy only the evidence when it arrives.